| Dr Jason Meyer, MD | |
|
3535 Southern Blvd, Kettering, OH 45429-1221 | |
| (937) 395-8849 | |
| Not Available |
| Full Name | Dr Jason Meyer |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 3535 Southern Blvd, Kettering, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215129283 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kettering Medical Center | Kettering, OH | Hospital |
| Grandview And Southview Hospitals | Dayton, OH | Hospital |
| Soin Medical Center | Beaver creek, OH | Hospital |
| Fort Hamilton Hughes Memorial Hospital | Hamilton, OH | Hospital |
| Kettering Medical Center - Sycamore | Miamisburg, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Pathology Services Inc | 7416846910 | 8 |
| Kettering Pathology Associates Inc | 8426040171 | 10 |
News Archive
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors.
For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.
EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
› Verified 3 days ago
| Entity Name | Regional Pathology Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285683904 PECOS PAC ID: 7416846910 Enrollment ID: O20040312000744 |
News Archive
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors.
For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.
EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
› Verified 3 days ago
| Entity Name | Kettering Pathology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285683946 PECOS PAC ID: 8426040171 Enrollment ID: O20040401000793 |
News Archive
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors.
For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.
EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Meyer, MD 3535 Southern Blvd, Kettering, OH 45429-1221 Ph: (937) 395-8849 | Dr Jason Meyer, MD 3535 Southern Blvd, Kettering, OH 45429-1221 Ph: (937) 395-8849 |
News Archive
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors.
For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.
EBiothera's Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG administered in combination with cetuximab (Erbitux), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
› Verified 3 days ago
Dr. William T Amos Iii, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4735 Walther Cir, Kettering, OH 45429 Phone: 937-307-4239 | |
Ersie Pouagare, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3535 Southern Blvd, Kettering, OH 45429 Phone: 937-395-8849 | |
Scott Joseph Arnold, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3535 Southern Blvd., Attn: Surgical Pathology Dept, Kettering, OH 45429 Phone: 937-395-8849 Fax: 937-395-8350 | |
Yvonne Gwyneth Dowdy, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3535 Southern Blvd., Kettering, OH 45429 Phone: 937-395-8849 Fax: 937-395-8350 | |
Dr. Angie Marie Elsheikh, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3535 Southern Blvd., Kettering, OH 45429 Phone: 937-395-8849 Fax: 937-395-8350 | |
Richard Joseph Pelstring, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 3535 Southern Blvd., Kettering, OH 45429 Phone: 937-395-8849 Fax: 937-395-8350 |